Latest News


Findings Indicate Low Risk of Liver Dysfunction With Elinzanetant in U.S. Menopausal Population
0:30
Findings Indicate Low Risk of Liver Dysfunction With Elinzanetant in U.S. Menopausal Population
18 hours ago
by
James Simon, MD, CCD, MSCP, IF, FACOG(+1 more)
Why Pharmacists Are Essential to Your Medical Care, Not Just Rx Fillers
1:10.799999999999997
Why Pharmacists Are Essential to Your Medical Care, Not Just Rx Fillers
21 hours ago
by
Megan Dulohery Scrodin, MD(+1 more)
Advances in Taste Masking Technologies for Oral Drug and Supplement Delivery
0:34
Advances in Taste Masking Technologies for Oral Drug and Supplement Delivery
4 days ago
by
David Mastropietro, R.Ph., Ph.D.(+1 more)
Spotting and Fixing Medication Problems Before They Arise
0:31
Spotting and Fixing Medication Problems Before They Arise
9 days ago
by
Sarah Nelson, PharmD(+1 more)
Why Trust Makes Pharmacists Key to Public Health
0:43
Why Trust Makes Pharmacists Key to Public Health
10 days ago
by
Samantha Picking, PharmD(+1 more)
Jolene Bostwick, PharmD, BCPS, BCPP.
0:41
What Is Psychotropic Stewardship?
10 days ago
by
Jolene Bostwick, PharmD, BCPS, BCPP(+1 more)
Updates in Chronic Inflammatory Demyelinating Polyneuropathy Treatment
0:52
Updates in Chronic Inflammatory Demyelinating Polyneuropathy Treatment
11 days ago
by
Amy Duong, PharmD, BCACP(+1 more)
Pharmacists Encouraged to Contact Lawmakers Amid Government Shutdown
0:50
Pharmacists Encouraged to Contact Lawmakers Amid Government Shutdown
15 days ago
by
Ron Lanton III, Esq(+1 more)
Management Considerations for Patients Receiving Zongertinib in NSCLC
0:58
Management Considerations for Patients Receiving Zongertinib in NSCLC
17 days ago
by
Joshua Sabari, MD(+1 more)
"Getting Closer" to Improved Outcomes and Reimagined Treatment Approaches in Multiple Myeloma, Expert Says
0:46
"Getting Closer" to Improved Outcomes and Reimagined Treatment Approaches in Multiple Myeloma, Expert Says
22 days ago
by
Gillian McGovern, Associate Editor(+1 more)

Podcasts



Continuing Medical Education


All News

A stem cell with prominent nucleus and vesicles represents regeneration potential cellular therapy and the promise of personalized medicine and tissue engineering. | Image Credit: kaliel | stock.adobe.com

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.